Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Serologicals Corporation
David Dodd assumed the role of chief executive at the Canadian oncology company in April and has clear plans to create a revenue stream that will help finance its portfolio of oncology candidates.
A new crop of companies deals head-on with Big Pharma's biggest out-licensing problems--transaction cost and the "embarrassment factor." Solving both involves strategies to make the extra work of out-licensing worthwhile for their large partners. In particular, after years of resisting the idea, they're now allowing their Big Pharma partners the right to buy back the compounds, usually after clinical proof of concept.
In this issue, we present another installment of our quarterly review of dealmaking-for October-December 2004. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.
In this issue, we present another installment of our quarterly review of dealmaking-for July-September 2004. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Drug Discovery Tools
- Large Molecule
Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.